504 related articles for article (PubMed ID: 25940550)
1. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9.
Abrahimi P; Chang WG; Kluger MS; Qyang Y; Tellides G; Saltzman WM; Pober JS
Circ Res; 2015 Jul; 117(2):121-8. PubMed ID: 25940550
[TBL] [Abstract][Full Text] [Related]
2. A platform for reverse genetics in endothelial cells.
Kok FO; Lawson ND
Circ Res; 2015 Jul; 117(2):107-8. PubMed ID: 26139853
[No Abstract] [Full Text] [Related]
3. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression.
Merola J; Reschke M; Pierce RW; Qin L; Spindler S; Baltazar T; Manes TD; Lopez-Giraldez F; Li G; Bracaglia LG; Xie C; Kirkiles-Smith N; Saltzman WM; Tietjen GT; Tellides G; Pober JS
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31527312
[TBL] [Abstract][Full Text] [Related]
4. Single-step generation of gene knockout-rescue system in pluripotent stem cells by promoter insertion with CRISPR/Cas9.
Matsunaga T; Yamashita JK
Biochem Biophys Res Commun; 2014 Feb; 444(2):158-63. PubMed ID: 24462858
[TBL] [Abstract][Full Text] [Related]
5. The combinational use of CRISPR/Cas9-based gene editing and targeted toxin technology enables efficient biallelic knockout of the α-1,3-galactosyltransferase gene in porcine embryonic fibroblasts.
Sato M; Miyoshi K; Nagao Y; Nishi Y; Ohtsuka M; Nakamura S; Sakurai T; Watanabe S
Xenotransplantation; 2014; 21(3):291-300. PubMed ID: 24919525
[TBL] [Abstract][Full Text] [Related]
6. Genome editing for human gene therapy.
Meissner TB; Mandal PK; Ferreira LM; Rossi DJ; Cowan CA
Methods Enzymol; 2014; 546():273-95. PubMed ID: 25398345
[TBL] [Abstract][Full Text] [Related]
7. The application of genome editing in studying hearing loss.
Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
[TBL] [Abstract][Full Text] [Related]
8. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
[TBL] [Abstract][Full Text] [Related]
9. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.
Joung J; Konermann S; Gootenberg JS; Abudayyeh OO; Platt RJ; Brigham MD; Sanjana NE; Zhang F
Nat Protoc; 2017 Apr; 12(4):828-863. PubMed ID: 28333914
[TBL] [Abstract][Full Text] [Related]
10. Production of knockout mice by DNA microinjection of various CRISPR/Cas9 vectors into freeze-thawed fertilized oocytes.
Nakagawa Y; Sakuma T; Sakamoto T; Ohmuraya M; Nakagata N; Yamamoto T
BMC Biotechnol; 2015 May; 15():33. PubMed ID: 25997509
[TBL] [Abstract][Full Text] [Related]
11. Using CRISPR/Cas9 Technology for Manipulating Cell Death Regulators.
Kueh AJ; Herold MJ
Methods Mol Biol; 2016; 1419():253-64. PubMed ID: 27108444
[TBL] [Abstract][Full Text] [Related]
12. Genome engineering using CRISPR-Cas9 system.
Cong L; Zhang F
Methods Mol Biol; 2015; 1239():197-217. PubMed ID: 25408407
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18.
Chu HW; Rios C; Huang C; Wesolowska-Andersen A; Burchard EG; O'Connor BP; Fingerlin TE; Nichols D; Reynolds SD; Seibold MA
Gene Ther; 2015 Oct; 22(10):822-9. PubMed ID: 26043872
[TBL] [Abstract][Full Text] [Related]
15. Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells.
Gong H; Liu M; Klomp J; Merrill BJ; Rehman J; Malik AB
Sci Rep; 2017 Feb; 7():42127. PubMed ID: 28198371
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 mediated generation of stable chondrocyte cell lines with targeted gene knockouts; analysis of an aggrecan knockout cell line.
Yang M; Zhang L; Stevens J; Gibson G
Bone; 2014 Dec; 69():118-25. PubMed ID: 25260929
[TBL] [Abstract][Full Text] [Related]
17. Generation of Genetic Knockouts in Myeloid Cell Lines Using a Lentiviral CRISPR/Cas9 System.
Baker PJ; Masters SL
Methods Mol Biol; 2018; 1714():41-55. PubMed ID: 29177854
[TBL] [Abstract][Full Text] [Related]
18. Generation of B cell-deficient pigs by highly efficient CRISPR/Cas9-mediated gene targeting.
Chen F; Wang Y; Yuan Y; Zhang W; Ren Z; Jin Y; Liu X; Xiong Q; Chen Q; Zhang M; Li X; Zhao L; Li Z; Wu Z; Zhang Y; Hu F; Huang J; Li R; Dai Y
J Genet Genomics; 2015 Aug; 42(8):437-44. PubMed ID: 26336800
[TBL] [Abstract][Full Text] [Related]
19. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of Bombyx Wnt1 during embryogenesis using the CRISPR/Cas9 system.
Zhang Z; Aslam AF; Liu X; Li M; Huang Y; Tan A
J Insect Physiol; 2015 Aug; 79():73-9. PubMed ID: 26070541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
